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Abstract
OBJECTIVES—Somatosensory amplification is the experience of sensing everyday bodily
sensations as intense, agitating, and unpleasant. Using data from menopausal breast cancer
survivors and midlife women without cancer, the study purposes were to (1) explore the
psychometric properties of the Somatosensory Amplification Scale and (2) to describe
somatosensory amplification and its relationship to menopausal symptoms of hot flashes, mood
and sleep disturbance.
STUDY DESIGN—This was a cross-sectional, descriptive, correlational study using
demographic, e-diary, and questionnaire data from 99 breast cancer survivors and 138 midlife
women.
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MAIN OUTCOME MEASURES—Somatosensory amplification, hot flashes (frequency,
severity, bother, interference, perceived control), mood, and sleep.
RESULTS—Cronbach’s alphas for the scale were low. When an 8-item version of the scale was
evaluated, alphas improved and item-total correlations remained strong or improved. Midlife
women and breast cancer survivors did not have significantly different somatosensory
amplification total or item scores after adjusting for group differences in demographics.
Somatosensory amplification was significantly correlated with hot flash interference, perceived
control over hot flashes, and mood and sleep disturbance in both groups but the patterns of
correlations differed slightly between groups and depending on whether the 10-item or 8-item
scale was used.
CONCLUSION—Somatosensory amplification may be a relevant concept to assess in relation to
the menopausal symptom experience of midlife women with and without breast cancer as it may
represent a potential intervention target to improve the menopausal symptom experience.
Keywords
Menopause; menopausal symptoms; somatosensory amplification; women’s health
INTRODUCTION
Somatosensory amplification refers to the ability to perceive every day or normal bodily
sensations at a more intense, agitating, and unpleasant level [1]. Somatosensory
amplification is sometimes referred to as “amplification”. Greater understanding of
somatosensory amplification and menopausal symptoms could provide a better
understanding of women’s symptom experiences. Other studies have linked somatosensory
amplification to symptoms in individuals with upper respiratory infections and migraines
[2], as well as overall health worries [3]. Because breast cancer survivors are known to be
more symptomatic at menopause than midlife menopausal women [4], understanding
differences in somatosensory amplification between these two groups could lead to a new
avenue for intervention research.
To the best of our knowledge, there is no published research exploring somatosensory
amplification in relation to menopausal symptoms. Using the PubMed search engine, a
literature search was conducted to identify articles on somatosensory amplification and
menopausal symptoms. The goal was to find English language, human subjects, original
research studies. Search phrases were (1) (somatosensory amplification) and (menopause or
hot flashes or sleep) and 2) (somatosensory amplification) and (menopause and mood). The
first search phrase produced 2 results, neither of which was relevant. The second search
phrase produced no articles. These search results indicated that somatosensory amplification
had not been previously studied in menopausal women, suggesting the need to explore the
psychometric properties of the Somatosensory Amplification Scale (SSAS) in this
population and explore relationships between this concept and menopausal symptoms.
Therefore, using data from menopausal breast cancer survivors and midlife women without
cancer, the study purposes were to (a) explore the psychometric properties of the
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Somatosensory Amplification Scale and (b) to describe somatosensory amplification and its
relationship to menopausal symptoms of hot flashes, mood and sleep disturbance. We
explored Cronbach’s alpha and item-total correlations as measures of internal consistency
reliability, group differences in somatosensory amplification, and relationships between
somatosensory amplification and menopausal symptoms.
METHODS
This was a cross-sectional, descriptive, correlational study. Data used was from information
collected at baseline of a larger hot flash intervention study. All study procedures were
approved by an Institutional Review Board and the cancer center’s Scientific Review
Committee. The study population included 99 breast cancer survivors and 138 midlife
women without cancer [5]. Participants were recruited from the breast cancer and high risk
clinics at a Midwestern National Cancer Institute-designated cancer center and from the
community using mass mailings of brochures and flyers, website and newsletter
advertisements, and word of mouth. Eligible and interested women provided written
informed consent, written approval to use health information, and completed a packet of
questionnaires at baseline before being randomized in the intervention study. Data from all
women who completed baseline questionnaires are used here for this analysis.
Demographics were assessed using a questionnaire. Questions were both personal
characteristics (e.g., age, race, marital status) and medical information (e.g., comorbidities,
use of hot flash treatments).
The 10-item Somatosensory Amplification Scale includes a 5-item Likert-type response
scale for participants to indicate the degree they are bothered by different somatic and
visceral sensations [6]. A higher total score suggests greater symptom amplification with the
scores ranging between 10 and 50.
An electronic hot flash diary was used to collect real-time, prospective ratings of hot flash
frequency, severity and bother. Women carried a small monitor in a waist pack and pressed
buttons on the monitor each time they had a hot flash. Severity and bother of each hot flash
was rated by pressing the buttons and using a 0 (not at all) to 10 (extremely) scale. Women
wore the monitor for a minimum of 24-hours and a maximum of 7-days based on their
personal preference. Twenty-four hour average hot flash frequency, severity, and bother
were calculated.
The 10-item Hot Flash Related Daily Interference Scale [7] was used to assess hot flash
interference or disruption. Participants rated each of the items using a 0 to 10 numeric rating
scale. Scores range from 0 to 100 with higher scores indicating greater interference.
The Perceived Control over Hot Flashes Index (PCI) is a 15-item questionnaire (e.g., If I do
all the right things, I can successfully manage hot flush symptoms) that uses a 4-point Likert
scale (ranging from ‘strongly disagree’ to ‘strongly agree’) [8]. Higher total scores convey
more perceived control over hot flashes.
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The 37-item Profile of Mood States (POMS) questionnaire is a psychological self-report
assessment using a 5-point Likert scale that measures affective mood states [9]. It yields a
total mood disturbance score as well as 6 sub-scores with higher scores signifying greater
mood disturbance on all except vigor/activity. The subscales are tension/anxiety, anger/
hostility, fatigue/inertia, depression/dejection, vigor/activity and confusion/bewilderment.
The Pittsburgh Sleep Quality Index (PSQI) is a self-rated questionnaire that evaluates sleep
quality and patterns over the past month [10]. Nineteen items generate seven subscale
scores: sleep quality, sleep latency, sleep duration, sleep disturbance, sleep medication,
daytime sleep and sleep efficiency. These seven scores are used to distinguish good sleep
from poor sleep and the total of these subscales produces one global score. A global sum of
5 or greater signifies a poor sleeper.
Descriptive statistics (means, standard deviations, frequencies, percentages) were used to
describe demographic characteristics in each group. Cronbach’s alpha coefficients item-total
Pearson correlations for the SSAS were calculated in each group. Cronbach’s alpha is a
measure of internal consistency reliability, or a measure of how similar the scale items are to
one another. Alpha ranges from 0 to 1.00 with >.70 generally seen as an acceptable cutoff
for a new scale and >.80 acceptable for an existing scale. Between group comparisons on
demographics and baseline measures were done using t-tests and chi-squared analyses.
Pearson correlations were used to evaluate relationships between item and total scores in
both groups. An analysis of covariance was done to compare somatosensory amplification
between groups controlling for baseline demographic differences. Spearman correlations
were used to evaluate relationships between total scores and menopausal symptom variables
because of the skewed distribution of the latter. Because this was a correlative study from a
larger clinical trial [5] and because no formal hypotheses were stipulated for this descriptive
analysis, no corresponding sample size justification was made related to these outcomes in
the original clinical trial protocol. Given the descriptive/exploratory nature of our analyses,
our moderately large sample size seemed appropriate to address our purpose.
RESULTS
Sample Characteristics
As shown in Table 1, there were no group differences in ethnicity, employment status,
menopausal status, age, body mass index, or years of education. However, compared to
midlife women, breast cancer survivors were more likely to be White, married, have less
difficulty paying for basics, less likely to be smokers, more likely to be using a hot flash
treatment, more likely to be taking Tamoxifen/aromatase inhibitor (both of which cause hot
flashes) and using more medications in general. Breast cancer survivors were a mean of 7.57
years post diagnosis (SD = 7.61).
There were no differences between groups in hot flash frequency, severity, bother,
interference, perceived control over hot flashes or sleep (p > .05). Total mood disturbance
was significantly higher in the midlife women than in the breast cancer survivors (p < 0.05).
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SSAS Psychometrics
When using the full 10-item scale, Cronbach’s alpha coefficient was sub-optimal in both
groups (0.66 breast cancer group, 0.68 midlife women group) and item-total correlations
ranged from 0.270 to 0.610 in the breast cancer group and 0.365 to 0.615 in the midlife
women (Table 2). Based on these results, we removed the items most poorly correlated with
total scores in both groups: item #1 “I can't stand smoke, smog, or pollutants in the air” and
item #3 “When I bruise myself, it stays noticeable for a long time”. Removal of these two
items resulted in slightly improved alphas (0.70 both groups). For the 8-item scale, most
item-total correlations improved ranging from 0.441 to 0.660 in the breast cancer group and
0.447 to 0.644 in the menopausal women (Table 2). For consistency with other studies and
accounting for the psychometric instability, we present findings for both the full 10-item
original SSAS and the modified 8-item SSAS.
Group Differences in Somatosensory Amplification
Group differences in SSAS total scores and SSAS items are shown in Table 3. Although
there was a tendency for total and items scores to be higher in midlife women, group
differences were not statistically significant after adjusting for covariates. Findings held for
both the 10-item and 8-item versions of the scale. Thus, both groups appeared to have the
same level of somatosensory amplification.
Correlations Between Somatosensory Amplification and Menopausal Symptoms
The 10-item SSAS total scores were significantly related to hot flash interference and
perceived control (Table 4). In both groups, greater somatosensory amplification was
associated with greater hot flash interference and less perceived control over hot flashes.
Somatosensory amplification was also related to mood in both groups, though the pattern of
correlations differed slightly (Table 4). In breast cancer survivors and midlife women,
higher somatosensory amplification was related to increased tension/anxiety, fatigue/inertia/
depression/dejection, and confusion/bewilderment. However, higher somatosensory
amplification was related to greater anger/hostility only among the menopausal women. In
addition, greater somatosensory amplification was related to poorer sleep (Table 4). In both
breast cancer survivors and menopausal women, low sleep quality, higher sleep disturbances
and increased daytime sleepiness were significantly related to a higher somatosensory
awareness. In breast cancer survivors only, greater amplification was significantly related to
longer sleep duration. Results for the 8-item SSAS total scores followed a similar pattern
with only a few exceptions. In the breast cancer group, the 8-item SSAS showed no
relationship to perceived hot flash control and a negative relationship with vigor/activity.
CONCLUSIONS
The findings in this study offer a new understanding concerning the concept of
somatosensory amplification and the role it plays in the hot flash, mood and sleep
experience of healthy menopausal women and menopausal women with a history of breast
cancer. No difference was found in the SSAS total and individual item total between the two
groups. This indicates that somatosensory amplification affects menopausal women at a
similarly steady level regardless of exposure to breast cancer diagnosis and treatment. The
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effect of somatosensory amplification on hot flash experience appears to be one that can be
generalized across women. Both groups reported comparable levels of hot flash severity,
frequency, and bother as well as mood and sleep disturbance in contrast to prior studies
showing a more severe symptom experience in cancer survivors. [4, 11] This similarity may
have (a) been due to the fact that all were seeking treatment in this intervention study and (b)
contributed to the lack of group differences in somatosensory amplification.
Somatosensory amplification was related to hot flash interference and perceived control but
not with other hot flash variables. It is important to note that the hot flash variables that had
no correlation with somatosensory amplification were variables that were measured in real-
time using the electronic diary while the other variables were assessed over the past week or
two weeks using standardized questionnaires. This may indicate the necessity to look further
into women’s personal interpretation of their hot flash experience and to seek out methods
may positively alter that interpretation. This finding also seems to point to the need for
interventions that focus more on the perception of hot flashes instead of on trying to
diminish the symptom itself.
Higher sleep and mood disturbance scores were both found to be significantly related to a
higher somatosensory amplification for breast cancer survivors and midlife women. These
outcomes are consistent with the results found in the literature review that link poor sleep
with mood disturbance in the overall menopausal experience [12]. An individual who has a
heightened somatosensory awareness could possibly perceive poor sleep and mood
disturbance as more distressing than the average individual, though this was not directly
studied here.
Limitations of this study included the following. The Cronbach’s alpha calculated for the
SSAS was low (alpha= 0.66). Improved alphas were seen with a shorter version of the scale
but they were still considered low for an established scale (alpha = 0.70). It is possible that
the SSAS is not a reliable tool to use to measure the tendency to amplify somatic symptoms.
Data used in this analysis were cross-sectional and therefore do not provide information
about whether or how these relationships might change over time. The sample had a
relatively high percentage of Caucasian women. There were more women without cancer
available for the analysis than women with breast cancer.
The results of this study suggest that future menopausal symptom management interventions
for midlife women could focus on altering somatosensory amplification. Assisting women to
change how they sense and interpret their menopausal symptoms may help women decrease
hot flash interference and mood and sleep disruption and may also help increase a woman’s
perceived control over hot flashes. Focusing interventions on decreasing somatosensory
awareness may have a successful effect on increasing the perception of sleep quality.
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Table 1
Group Differences in Demographics and Menopausal Symptoms
BCS
% (n)
MW
% (n) P
Ethnicity 0.642
  Latina 1 (1) 2 (3)
  Non-Latina 99 (98) 98 (135)
Race <.001
  White/Caucasian 86 (85) 57 (78)
  Other 14 (14) 43 (60)
Marital <.001
  Married / living with partner 75 (74) 53 (73)
  Single, widowed 20 (20) 4 (5)
  Other 5 (5) 43 (60)
Employment 0.841
  Full time 63 (62) 65 (90)
  Part time 13 (13) 14 (19)
  Not employed 24 (24) 21 (29)
Difficulty paying for basics 0.024
  None 82 (81) 66 (91)
  Some 15 (15) 27 (37)
  A lot 3 (3) 7 (10)
Smoker 0.393
  Never 72 (71) 59 (81)
  Former or current 28 (28) 41 (57)
Menopausal status 0.088
  Early peri / late peri 1 (1) 5 (6)
  Early post 9 (9) 16 (21)
  Late post 90 (85) 79 (102)
Current use of hot flash treatments 0.031
  No 41 (40) 55 (76)
  yes 59 (58) 45 (62)
Use of SERM <.001
  No, not currently 64 (63) 99 (136)
  Yes, currently 36 (36) 1 (2)
Use of AI <.001
  No, not currently 75 (74) 100 (138)
  Yes, currently 25 (25) 0 (0)
(M, SD) (M, SD) p
Age 53.10 (8.10) 52.36 (5.17) 0.388
Body mass index 28.80 (6.02) 30.17 (8.01) 0.136
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BCS
% (n)
MW
% (n) P
Years of education 15.22 (2.48) 14.78 (2.13) 0.146
Concurrent medications 2.74 (2.00) 1.96 (1.93) 0.003
Comorbid conditions 2.11 (1.05) 1.46 (1.35) <.001
Years since last menses 7.57 (7.61) 6.32 (7.00) 0.211
Electronic hot flash diary days 3.82 (3.30) 4.00 (2.65) 0.600
24-hour hot flash frequency 6.94 (4.30) 6.34 (4.39) 0.303
24-hour hot flash severity 2.07 (1.59) 2.08 (1.65) 0.940
24-hour hot flash bother 1.83 (1.49) 1.88 (1.63) 0.818
Total hot flash related daily interference 39.98 (24.61) 45.49 (24.08) 0.091
Perceived control over hot flashes 37.59 (5.05) 37.61 (4.72) 0.9741
POMS total mood disturbance 39.04 (22.48) 45.62 (24.86) 0.0418
PSQI Global sleep 7.84 (3.19) 8.07 (3.68) 0.620
SERM = selective estrogen receptor modulator, AI = aromatase inhibitor
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Table 2
SSAS Item-Total Correlations by Group
10-item SSAS Total 8-item SSAS Total
SSAS Item BCS MW BCS MW
1. I can't stand smoke, smog, or pollutants in the air. 0.452*** 0.434*** NA NA
2. I am often aware of various things happening within my body. 0.565*** 0.500*** 0.520*** 0.462***
3. When I bruise myself, it stays noticeable for a long time. 0.270** 0.365*** NA NA
4. I sometimes can feel the blood flowing in my body. 0.596*** 0.417*** 0.591*** 0.447***
5. Sudden loud noises really bother me. 0.425*** 0.615*** 0.441*** 0.581***
6. I can sometimes hear my pulse or my heartbeat throbbing in my ear. 0.598*** 0.518*** 0.660*** 0.558***
7. I hate to be too hot or too cold. 0.610*** 0.571*** 0.601*** 0.599***
8. I am quick to sense the hunger contractions in my stomach. 0.494*** 0.559*** 0.563*** 0.628***
9. Even something minor, like an insect bite or a splinter really bothers me. 0.519*** 0.602*** 0.593*** 0.644***
10. I can't stand pain. 0.514*** 0.559*** 0.601*** 0.605***
Breast cancer survivors (BCS) n=99; Midlife women (MW) n=138;
*p<.05,
**p<.01,
***p<.001
NA – item not included in the 8-item total score
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Table 3
Differences in SSAS Total Scores and SSAS Items Between Groups
BCS
M (SD)
MW
M (SD) p
a
10-item total score 26.55 (5.75) 28.41 (6.13) 0.3666
8-item total scoreb 20.20 (5.09) 22.01 (5.29) 0.5056
1. I can't stand smoke, smog, or pollutants in the air. 3.72 (1.33) 6.62 (1.38) 0.5927
2. I am often aware of various things happening within my body. 3.64 (1.05) 3.87 (0.97) 0.4005
3. When I bruise myself, it stays noticeable for a long time. 2.63 (1.30) 2.78 (1.27) 0.0499
4. I sometimes can feel the blood flowing in my body. 1.58 (0.96) 1.74 (1.12) 0.6795
5. Sudden loud noises really bother me. 2.24 (1.18) 2.49 (1.20) 0.0572
6. I can sometimes hear my pulse or my heartbeat throbbing in my ear. 2.26 (1.28) 2.22 (1.35) 0.8373
7. I hate to be too hot or too cold. 3.84 (1.12) 4.06 (0.99) 0.8178
8. I am quick to sense the hunger contractions in my stomach. 2.86 (1.23) 3.15 (1.24) 0.6037
9. Even something minor, like an insect bite or a splinter really bothers me. 1.69 (0.97) 1.95 (1.16) 0.8471
10. I can't stand pain. 2.10 (1.11) 2.54 (1.28) 0.9044
Breast cancer survivors (BCS) n=98; Midlife women (MW) n=138;
*p<.05,
**p<.01,
***p<.001
ap value of differences controlling for demographic differences in race, marital status, ability to pay for basics, smoking, current use of hot flash
treatment (yes, no), current use of SERM/AI (yes, no), and number of concurrent medications.
b8-item total omits items #1 and #3.
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Table 4
Spearman Correlations Between Somatosensory Amplification (SSAS) and Menopausal Symptoms
10-item SSAS 8-item SSAS
BCS MW BCS MW
HF frequency 0.03 −0.01 −0.05 −0.02
HF severity 0.07 0.03 0.08 0.03
HF bother 0.09 0.11 0.10 0.10
HF interference 0.39*** 0.30*** 0.34*** 0.30***
HF perceived control
−0.24* −0.19* −0.19 −0.17*
Total mood disturbance 0.36*** 0.25** 0.38*** 0.29***
  Tension / Anxiety 0.36*** 0.26** 0.37** 0.31***
  Anger/ Hostility 0.15 0.24** 0.17 0.29***
  Fatigue/ Inertia 0.37*** 0.18* 0.39*** 0.18*
  Depression/ Dejection 0.28** 0.21* 0.30** 0.24**
  Vigor/ Activity −0.19 −0.15
−0.23* −0.13
  Confusion/ Bewilderment 0.33*** 0.23** 0.36*** 0.27**
Global sleep disturbance 0.26** 0.14 0.27** 0.14
  Sleep Quality 0.24* 0.17* 0.26* 0.14
  Sleep Latency 0.03 0.06 0.03 0.09
  Sleep Duration 0.21* −0.04 0.25* −0.05
  Sleep Disturbance 0.24* 0.20* 0.23* 0.22**
  Sleep Medication 0.02 0.15 0.01 0.16
  Daytime Sleep 0.40*** 0.33*** 0.41*** 0.34***
  Sleep Efficiency 0.01 0.01 0.02 0.01
Breast cancer survivors (BCS) n=99; Midlife women (MW) n=138;
*p<.05,
**p<.01,
***p<.001
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